mk-1029
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01343407)
Timeline
Indications
Studied for
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545031 ↗
Also known as
- mk-1029
- mk-1029
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02720081 | Phase 2 | May 11, 2016 | Merck |
| NCT01624974 | Phase 2 | Aug 1, 2012 | Merck |
| NCT01656395 | Phase 2 | Aug 1, 2012 | Merck |
| NCT01370317 | Phase 1 | Jun 1, 2011 | Merck |
| NCT01343407 | Phase 1 | Apr 1, 2011 | Merck |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 5 | 5 | 2 | 2011 |
1 organizations
Page 1 / 1